Generated by AI
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing precision therapies for central nervous system disorders characterized by neuronal excitability and excitation-inhibition imbalance. Praxis Precision Medicines, Inc. applies genetic and translational neuroscience insights to create treatments for movement disorders, epilepsy, and selected psychiatric and neurological conditions. Its portfolio includes both small-molecule programs and antisense oligonucleotide therapies, supported by proprietary research platforms designed to match drug candidates to specific biological targets and patient subgroups. The company’s work centers on disorders where shared neural circuitry and genetic mechanisms may help guide more targeted therapeutic development. Praxis Precision Medicines, Inc. operates as a research-driven biotech organization with a pipeline that spans multiple CNS indications and reflects a precision medicine approach to brain health.
Website99 High Street
Boston, MA, 02110
United States
The latest articles about PRAX.
Praxis Precision Medicines has delivered very strong multi year gains, and the latest move leaves investors asking whether the current share price still lines up with what its book value can support. With the story increasingly shaped by expectations rather than cash flow today, the question is how much balance sheet backing the stock really has at this level. Over the past 3 years, Praxis Precision Medicines has produced a return of roughly 24 times an initial investment. This puts a lot of...
Summary of Nov 17's posts. Generated by AI.
Summary of Dec 29's posts. Generated by AI.
Summary of Nov 12's posts. Generated by AI.
Investors talking about PRAX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.